March 20, 2018, 2:04 am
Facebook iconTwitter iconYouTube iconGoogle+ icon
1 Philippine Peso = 0.07076 UAE Dirham
1 Philippine Peso = 2.0501 Albanian Lek
1 Philippine Peso = 0.0343 Neth Antilles Guilder
1 Philippine Peso = 0.38842 Argentine Peso
1 Philippine Peso = 0.02496 Australian Dollar
1 Philippine Peso = 0.0343 Aruba Florin
1 Philippine Peso = 0.03854 Barbados Dollar
1 Philippine Peso = 1.59711 Bangladesh Taka
1 Philippine Peso = 0.03064 Bulgarian Lev
1 Philippine Peso = 0.00726 Bahraini Dinar
1 Philippine Peso = 33.73757 Burundi Franc
1 Philippine Peso = 0.01927 Bermuda Dollar
1 Philippine Peso = 0.02536 Brunei Dollar
1 Philippine Peso = 0.13218 Bolivian Boliviano
1 Philippine Peso = 0.0632 Brazilian Real
1 Philippine Peso = 0.01927 Bahamian Dollar
1 Philippine Peso = 1.24952 Bhutan Ngultrum
1 Philippine Peso = 0.18446 Botswana Pula
1 Philippine Peso = 385.7418 Belarus Ruble
1 Philippine Peso = 0.03849 Belize Dollar
1 Philippine Peso = 0.02523 Canadian Dollar
1 Philippine Peso = 0.01834 Swiss Franc
1 Philippine Peso = 11.71927 Chilean Peso
1 Philippine Peso = 0.12196 Chinese Yuan
1 Philippine Peso = 55 Colombian Peso
1 Philippine Peso = 10.83487 Costa Rica Colon
1 Philippine Peso = 0.01927 Cuban Peso
1 Philippine Peso = 1.72909 Cape Verde Escudo
1 Philippine Peso = 0.39802 Czech Koruna
1 Philippine Peso = 3.40713 Djibouti Franc
1 Philippine Peso = 0.11676 Danish Krone
1 Philippine Peso = 0.95896 Dominican Peso
1 Philippine Peso = 2.19576 Algerian Dinar
1 Philippine Peso = 0.2451 Estonian Kroon
1 Philippine Peso = 0.33786 Egyptian Pound
1 Philippine Peso = 0.52447 Ethiopian Birr
1 Philippine Peso = 0.01566 Euro
1 Philippine Peso = 0.03882 Fiji Dollar
1 Philippine Peso = 0.01381 Falkland Islands Pound
1 Philippine Peso = 0.01383 British Pound
1 Philippine Peso = 0.08486 Ghanaian Cedi
1 Philippine Peso = 0.90173 Gambian Dalasi
1 Philippine Peso = 173.4682 Guinea Franc
1 Philippine Peso = 0.14135 Guatemala Quetzal
1 Philippine Peso = 3.95511 Guyana Dollar
1 Philippine Peso = 0.15109 Hong Kong Dollar
1 Philippine Peso = 0.45397 Honduras Lempira
1 Philippine Peso = 0.11662 Croatian Kuna
1 Philippine Peso = 1.24432 Haiti Gourde
1 Philippine Peso = 4.86975 Hungarian Forint
1 Philippine Peso = 264.79768 Indonesian Rupiah
1 Philippine Peso = 0.06653 Israeli Shekel
1 Philippine Peso = 1.25202 Indian Rupee
1 Philippine Peso = 22.8131 Iraqi Dinar
1 Philippine Peso = 726.26201 Iran Rial
1 Philippine Peso = 1.91715 Iceland Krona
1 Philippine Peso = 2.44817 Jamaican Dollar
1 Philippine Peso = 0.01361 Jordanian Dinar
1 Philippine Peso = 2.04193 Japanese Yen
1 Philippine Peso = 1.94701 Kenyan Shilling
1 Philippine Peso = 1.31502 Kyrgyzstan Som
1 Philippine Peso = 76.72447 Cambodia Riel
1 Philippine Peso = 7.69364 Comoros Franc
1 Philippine Peso = 17.34104 North Korean Won
1 Philippine Peso = 20.59788 Korean Won
1 Philippine Peso = 0.00577 Kuwaiti Dinar
1 Philippine Peso = 0.0158 Cayman Islands Dollar
1 Philippine Peso = 6.21407 Kazakhstan Tenge
1 Philippine Peso = 159.5183 Lao Kip
1 Philippine Peso = 29.01156 Lebanese Pound
1 Philippine Peso = 3.00482 Sri Lanka Rupee
1 Philippine Peso = 2.52331 Liberian Dollar
1 Philippine Peso = 0.23064 Lesotho Loti
1 Philippine Peso = 0.05874 Lithuanian Lita
1 Philippine Peso = 0.01196 Latvian Lat
1 Philippine Peso = 0.02554 Libyan Dinar
1 Philippine Peso = 0.17689 Moroccan Dirham
1 Philippine Peso = 0.31757 Moldovan Leu
1 Philippine Peso = 0.96012 Macedonian Denar
1 Philippine Peso = 25.78035 Myanmar Kyat
1 Philippine Peso = 46.03083 Mongolian Tugrik
1 Philippine Peso = 0.15554 Macau Pataca
1 Philippine Peso = 6.76301 Mauritania Ougulya
1 Philippine Peso = 0.6368 Mauritius Rupee
1 Philippine Peso = 0.3 Maldives Rufiyaa
1 Philippine Peso = 13.74605 Malawi Kwacha
1 Philippine Peso = 0.35992 Mexican Peso
1 Philippine Peso = 0.07528 Malaysian Ringgit
1 Philippine Peso = 0.23044 Namibian Dollar
1 Philippine Peso = 6.87861 Nigerian Naira
1 Philippine Peso = 0.59692 Nicaragua Cordoba
1 Philippine Peso = 0.14861 Norwegian Krone
1 Philippine Peso = 2.00301 Nepalese Rupee
1 Philippine Peso = 0.02669 New Zealand Dollar
1 Philippine Peso = 0.00742 Omani Rial
1 Philippine Peso = 0.01927 Panama Balboa
1 Philippine Peso = 0.06293 Peruvian Nuevo Sol
1 Philippine Peso = 0.06089 Papua New Guinea Kina
1 Philippine Peso = 1 Philippine Peso
1 Philippine Peso = 2.12852 Pakistani Rupee
1 Philippine Peso = 0.06613 Polish Zloty
1 Philippine Peso = 106.35838 Paraguayan Guarani
1 Philippine Peso = 0.07013 Qatar Rial
1 Philippine Peso = 0.07303 Romanian New Leu
1 Philippine Peso = 1.108 Russian Rouble
1 Philippine Peso = 16.24143 Rwanda Franc
1 Philippine Peso = 0.07225 Saudi Arabian Riyal
1 Philippine Peso = 0.14897 Solomon Islands Dollar
1 Philippine Peso = 0.25942 Seychelles Rupee
1 Philippine Peso = 0.34781 Sudanese Pound
1 Philippine Peso = 0.15787 Swedish Krona
1 Philippine Peso = 0.02537 Singapore Dollar
1 Philippine Peso = 0.01381 St Helena Pound
1 Philippine Peso = 0.42786 Slovak Koruna
1 Philippine Peso = 147.01348 Sierra Leone Leone
1 Philippine Peso = 10.88632 Somali Shilling
1 Philippine Peso = 384.19653 Sao Tome Dobra
1 Philippine Peso = 0.16859 El Salvador Colon
1 Philippine Peso = 9.92254 Syrian Pound
1 Philippine Peso = 0.23065 Swaziland Lilageni
1 Philippine Peso = 0.60154 Thai Baht
1 Philippine Peso = 0.0462 Tunisian Dinar
1 Philippine Peso = 0.04308 Tongan paʻanga
1 Philippine Peso = 0.0755 Turkish Lira
1 Philippine Peso = 0.12954 Trinidad Tobago Dollar
1 Philippine Peso = 0.56091 Taiwan Dollar
1 Philippine Peso = 43.31406 Tanzanian Shilling
1 Philippine Peso = 0.50848 Ukraine Hryvnia
1 Philippine Peso = 70.36609 Ugandan Shilling
1 Philippine Peso = 0.01927 United States Dollar
1 Philippine Peso = 0.54624 Uruguayan New Peso
1 Philippine Peso = 156.45471 Uzbekistan Sum
1 Philippine Peso = 704.39304 Venezuelan Bolivar
1 Philippine Peso = 438.59343 Vietnam Dong
1 Philippine Peso = 2.01233 Vanuatu Vatu
1 Philippine Peso = 0.0486 Samoa Tala
1 Philippine Peso = 10.2763 CFA Franc (BEAC)
1 Philippine Peso = 0.05202 East Caribbean Dollar
1 Philippine Peso = 10.2763 CFA Franc (BCEAO)
1 Philippine Peso = 1.85954 Pacific Franc
1 Philippine Peso = 4.81503 Yemen Riyal
1 Philippine Peso = 0.23062 South African Rand
1 Philippine Peso = 99.99036 Zambian Kwacha
1 Philippine Peso = 6.97302 Zimbabwe dollar

Doctors for truth?

DR. Walden Bello, Ph.D., author of the below statement, was a member of the Philippine House of Representatives from 2009 to 2015. He resigned on principle from Congress, owing to differences with the administration of former president Benigno Aquino III on the Disbursement Acceleration Program (DAP), the Mamasapano Raid, and the Enhanced Defense Cooperation Agreement with the United States. His is the only recorded resignation-on-principle in the history of the Philippine Congress.

Citations in his statement directed me to another stakeholder in the tragedy--Dr. Maria Rosario Capeding--who wrote, with others, the “Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial.”--Lancet 2014; 384:1358-65. Dr. Capeding figured prominently in last December’s Dengvaxia inquiries.

Dr. Bello’s statement, on the Dengvaxia tragedy, initially released by Rappler: The Social News Network--below excerpted for limited space:

...There is in the “Doctors for Truth” position paper an implicit defense of the principals on the grounds that “there is no perfect vaccine.” The doctors conveniently forget that the purpose of rigorous clinical trials before a drug is brought to market is to reduce to as close to zero as possible the likelihood that, a) the drug will not work, or that b) it is dangerous, or that c) it has destabilizing side effects.

Measured by the yardstick of accepted statistical probabilities, Dengvaxia failed resoundingly, an event that is rigorously documented and explained in a Research Report that appeared in one of the leading journals of medical research, New England Journal of Medicine (Vol 373, No. 13, Sept 24, 2015), about half of whose authors were connected with Sanofi Pasteur.

The Report, which appeared before the Sanofi contract was made and the vaccination program was implemented, revealed that clinical trials showed that previously uninfected children of a certain age group showed a disturbingly higher risk than previously infected children to contract severe dengue after being vaccinated.

Indeed, so concerned were the editors that they accompanied the article with an editorial titled, “A Candidate Vaccine Walks a Tightrope.” According to the editorial, which hit the dengue research field like a thunderbolt, “Most eye-catching is the suggestion that CYD-TDV [Dengvaxia] vaccination was associated with an elevated risk of hospitalization for dengue among children younger than 9 years of age (but most markedly, among those 2 to 5 years of age) when they were naturally infected in the third year after vaccination.”

It concluded that “we still lack definitive immune correlates of protection or vaccine-associated disease risk. A lesson from these trials, and from our understanding of the natural history of dengue epidemiology, is that partial, waning immunity is a particularly unwelcome outcome after vaccination…Live vaccines need to be sufficiently potent in their infectiousness and replicative capacity to initiate immunity in both unexposed recipients and those with partial immunity…The bumpy road to a vaccine-based solution for dengue continues.” 

Despite this red light from a high-powered research team that included its own researchers, Sanofi Pasteur rushed a flawed product to the market to beat the competition and the DOH authorities pushed the vaccine on over 800,000 children in 2016, with no investigation of whether or not they had been previously exposed to dengue. One does not need to be a medical expert to come to the conclusion that the haste with which this vaccine was brought to the field was simply inexplicable from a public health point of view.

It’s a safe bet that very few of the doctors who signed the statement took the time to read the New England Journal of Medicine research report and editorial, for no self-respecting medical professional with the least bit of acquaintance with these documents, would have attached his or her signature to a statement that blithely defends the principals on the ground that “there is no perfect vaccine.”

The signatories compound their irresponsibility by saying that “we urge the DOH not to remove the vaccine from the market altogether,” allegedly to provide protection for those not yet found to be at risk of severe dengue infection stemming from vaccination. But contrary to its previous claim that Dengvaxia provided “consistent efficacy and longer-term safety profile in a study population 9 to16 years of age,” Sanofi retreated from this assertion and attached no age exemptions in its later, November 29, 2017, statement as to who should not be administered the vaccine.

Moreover, in banning the vaccine from the market altogether, the current DOH leadership is not panicking but simply adhering to the time-honored precautionary principle, which says, in this particular instance, that just because severe dengue infection has not yet surfaced in some categories of tested subjects that have been vaccinated does not mean that it is safe for the people in the same categories in the general population to use it.

The finding that those vaccinated who had no previous dengue infection could incur severe dengue demands that administering the drug to all age categories in the population, whether they have been previously infected by dengue or not, should be immediately withheld on the grounds that loss of immunity and susceptibility to severe dengue might take longer to emerge among some categories of the tested subjects. This does not mean a permanent ban, but one that can only be lifted after more rigorous trials carried out over a long period of time prove that the vaccine is safe for all age groups of previously infected or non-infected people.

The signatories bemoan the “expert bashing” that is taking place in public hearings. Have they asked themselves why this bashing is taking place in the first place? The distrust of experts stems from the fact that in the case of Dengvaxia, the experts have so spectacularly failed the people on a matter of public trust: the experts in Sanofi for rushing a dangerous vaccine to the market, and the experts at the DOH for carrying out a mass vaccination program that they knew – or should have known given the published findings--carried grave dangers for many of its intended recipients....

...But with the absence of even the slightest criticism of the principals and the misplaced focus on the opportunists, one might legitimately bring up the question whether the statement is not really an attempt by some in the medical profession to circle the wagons to protect colleagues who are likely to be guilty of criminal endangerment of public health. And given the lack of any criticism of Sanofi’s breath-taking wrongdoing, one might further raise the question if the “Doctors for Truth” statement is not really an attempt by the same people to also come to the defense of the pharmaceutical industry.

This is a legitimate issue since the industry’s relations with the medical profession everywhere in the world is very tight, with doctors and hospitals enjoying perks and donations from members of the pharmaceutical cartel that is cynically called “Big Pharma.”

Medical professionals serve on the international and local boards of the drug giants, and there is a revolving door between private practice, public health service, and corporate employment. For those passing through the revolving door, this translates into very lucrative income indeed, one that could be threatened by a more guarded public response to the products of the multi-billion-dollar industry.

In the interest of transparency, it might be good if the public were to demand that the “Doctors for Truth” fully disclose their professional associations, if any, to Sanofi and other members of the global pharmaceutical cartel, including their local affiliates and marketing arms. Thus concludes Dr. Bello.

Average: 3.3 (3 votes)

Column of the Day

China backs Philippines

By REY O. ARCILLA | March 20,2018
‘As an agency of the UN, the Office of the UN High Commissioner for Human Rights is expected to fulfill its duties within the framework set out by the purposes and principles of the UN Charter.’ – Chinese spokesman Lu Kang.

Opinion of the Day

Napoles redux

By ABIGAIL VALTE | March 20, 2018
‘Napoles can be weaponized against just about anyone that the administration dislikes.’